ADVANCED ACCELERATOR APPLICATIONS USA, INC

PLUVICTO

Manufacturer:

ADVANCED ACCELERATOR APPLICATIONS USA, INC

Pluvicto HCPCS:

A9607

HCPCS Code Descriptor:

Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie

Category:

A Code

Pluvicto NDCs:

69488-0010-61

Primary Type:

Imaging/Radiopharmaceutical

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Pluvicto:

PLUVICTO is an Imaging/Radiopharmaceutical drug manufactured by ADVANCED ACCELERATOR APPLICATIONS USA, INC and administered via the Intravenous route of administration. The A Code: A9607 is aligned to the drug PLUVICTO.

ACCESS PRICING AND MORE BY REGISTERING

A9607 Added Date:

October 1, 2022

A9607 Effective Date:

October 1, 2022

A9607 Termination Date:

HCPCS Active

Pluvicto billing and coding information can be found through Advanced Accelerator Applications Usa, Inc at the link below:
Pluvicto patient assistance information can be found through Novartis Patient Support at the URL: https://www.hcp.novartis.com/products/pluvicto/psma-positive-mcrpc/access/?site
PLUVICTO prescribing information can be found at the link below:
Information regarding PLUVICTO’s side effects can be found at MedlinePlus